Sun Pharmaceutical gains over 2% after settling antitrust litigation in US
DSIJ Intelligence / 10 Jul 2017
Sun Pharma was trading at Rs 560.45, up by Rs 10.75 or 1.96% as at 1016 hours on Monday, on the BSE. The stock had hit an intraday high of Rs 567.30.
After Sun Pharmaceutical announced that it has settled antitrust litigation in the US, Sun Pharmaceutical Industries gained over 2% in the early morning trade on Monday.
The Indian pharma giant made the announcement post market hours on Friday.
Sun Pharma was trading at Rs 560.45, up by Rs 10.75 or 1.96% as at 1016 hours on Monday, on the BSE. The stock had hit an intraday high of Rs 567.30.
“Sun Pharmaceutical Industries (Sun Pharma) and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in Modafinil Antitrust Litigation matter currently pending in the United States District Court for the Eastern District of Pennsylvania. The settlements extend to all claims brought by Apotex Corporation and the Retailer Purchaser Plaintiffs. The settlements remain are confidential,” the company said.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.